William Dupere, Vice President, Market Access Solutions

Background:

Since the end of the pharmaceutical industry’s “blockbuster era” and the beginning of its “specialty product era”, drug makers have used the term “hub services” to describe the often ponderous process of granting patients access to critical medications. While the term itself is a bit of a catch-all phrase, it constitutes such activities as benefits investigations, prior authorizations, reimbursement services, adherence programs, appeals, and nursing services, to name but a few. The conventional wisdom is that “hub services” are incredibly effective at helping patients more quickly obtain—and remain on—therapy.

The only thing that has been missing is the evidence that this is the case – until now.